22-Apr-2024
No headlines found.
QIAGEN N.V. to release results for Q1 2024 and hold webcast
Globe Newswire (Tue, 9-Apr 9:48 AM ET)
Globe Newswire (Wed, 3-Apr 4:05 PM ET)
Globe Newswire (Mon, 25-Mar 4:05 PM ET)
Globe Newswire (Mon, 18-Mar 4:05 PM ET)
QIAGEN announces Form 20-F annual report filing for 2023 results
Globe Newswire (Mon, 11-Mar 5:59 AM ET)
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery
Globe Newswire (Tue, 27-Feb 5:45 PM ET)
Globe Newswire (Tue, 27-Feb 4:05 PM ET)
Globe Newswire (Tue, 6-Feb 4:05 PM ET)
QIAGEN announces partnership with Penn State University to advance microbiome sciences
Globe Newswire (Thu, 25-Jan 10:00 AM ET)
Qiagen NV offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Qiagen N.V. Common Shares trades on the NYSE stock market under the symbol QGEN.
As of April 22, 2024, QGEN stock price climbed to $41.22 with 1,105,081 million shares trading.
QGEN has a beta of 0.97, meaning it tends to be less sensitive to market movements. QGEN has a correlation of 0.32 to the broad based SPY ETF.
QGEN has a market cap of $9.12 billion. This is considered a Mid Cap stock.
Last quarter Qiagen N.V. Common Shares reported $509 million in Revenue and $.55 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.02.
In the last 3 years, QGEN stock traded as high as $59.79 and as low as $35.81.
The top ETF exchange traded funds that QGEN belongs to (by Net Assets): IWR, IWD, IWS, ROBO, FXH.
QGEN has underperformed the market in the last year with a return of -12.0%, while the SPY ETF gained +22.3%. In the last 3 month period, QGEN fell short of the market, returning -11.4%, while SPY returned +3.9%. However, in the most recent 2 weeks QGEN has outperformed the stock market by returning +0.1%, while SPY returned -3.6%.
QGEN support price is $39.46 and resistance is $40.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QGEN stock will trade within this expected range on the day.